Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer.
Journal
Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
of treatment strategies for cervical cancer precursors, review of medical therapies and emerging therapeutics for treatment of cervical cancers, and updates on new approaches to treating early-stage cervical cancers.
Identifiants
pubmed: 37650664
doi: 10.1097/GRF.0000000000000790
pii: 00003081-202309000-00007
doi:
Banques de données
ClinicalTrials.gov
['NCT04831580', 'NCT03386734', 'NCT01658930', 'NCT01649089']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-515Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–723.
Lei J, Ploner A, Elfstrom KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383:1340–1348.
Falcaro M, Castanon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084–2092.
Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24:102–131.
Santesso N, Schunemann H, Blumenthal P, et al. World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2012;118:97–102.
Santesso N, Mustafa RA, Schunemann HJ, et al. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet. 2016;132:252–258.
Numnum TM, Kirby TO, Leath CA 3rd, et al. Straughn JM, Jr. A prospective evaluation of “see and treat” in women with HSIL Pap smear results: is this an appropriate strategy? J Low Genit Tract Dis. 2005;9:2–6.
Maza M, Schocken CM, Bergman KL, et al. Cervical precancer treatment in low- and middle-income countries: a technology overview. J Glob Oncol. 2017;3:400–408.
Keijser KG, Kenemans P, van der Zanden PH, et al. Diathermy loop excision in the management of cervical intraepithelial neoplasia: diagnosis and treatment in one procedure. Am J Obstet Gynecol. 1992;166:1281–1287.
Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013;12:CD001318.
Reich O, Pickel H, Lahousen M, et al. Cervical intraepithelial neoplasia III: long-term outcome after cold-knife conization with clear margins. Obstet Gynecol. 2001;97:428–430.
Reich O, Lahousen M, Pickel H, et al. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet Gynecol. 2002;99:193–196.
Luesley D, Shafi M, Finn C, et al. Haemorrhagic morbidity after diathermy loop excision: effect of multiple pre-treatment variables including time of treatment in relation to menstruation. Br J Obstet Gynaecol. 1992;99:82–83.
Conner SN, Frey HA, Cahill AG, et al. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. Obstet Gynecol. 2014;123:752–761.
Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489–498.
Oyesanya OA, Amerasinghe C, Manning EA. A comparison between loop diathermy conization and cold-knife conization for management of cervical dysplasia associated with unsatisfactory colposcopy. Gynecol Oncol. 1993;50:84–88.
Teoh D, Musa F, Salani R, et al. Diagnosis and management of adenocarcinoma in situ: a society of gynecologic oncology evidence-based review and recommendations. Obstet Gynecol. 2020;135:869–878.
Abdul-Karim FW, Fu YS, Reagan JW, et al. Morphometric study of intraepithelial neoplasia of the uterine cervix. Obstet Gynecol. 1982;60:210–214.
WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: world Health Organization. Updated 2019 https://www.ncbi.nlm.nih.gov/books/NBK549176/.
Randall TC, Sauvaget C, Muwonge R, et al. Worthy of further consideration: an updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019;118:81–91.
Duan L, Du H, Belinson JL, et al. Thermocoagulation versus cryotherapy for the treatment of cervical precancers. J Obstet Gynaecol Res. 2021;47:279–286.
Athanasiou A, Veroniki AA, Efthimiou O, et al. Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. Lancet Oncol. 2022;23:1097–1108.
D’Alessandro P, Arduino B, Borgo M, et al. Loop electrosurgical excision procedure versus cryotherapy in the treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of randomized controlled trials. Gynecol Minim Invasive Ther. 2018;7:145–151.
Grimm C, Polterauer S, Natter C, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012;120:152–159.
Polterauer S, Reich O, Widschwendter A, et al. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. Gynecol Oncol. 2022;165:23–29.
Fonseca BO, Possati-Resende JC, Salcedo MP, et al. Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: a Randomized Controlled Trial. Obstet Gynecol. 2021;137:1043–1053.
Helm CW, Lorenz DJ, Meyer NJ, et al. Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev. 2013;6:CD003296.
Rahangdale L, Lippmann QK, Garcia K, et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol. 2014;210:314 e1–314 e8.
Bossens M, Jost M, Van Pachterbeke C, et al. Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation. Int J Clin Pharmacol Ther. 2018;56:134–141.
Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol. 2009;115:69–74.
Hampson L, Maranga IO, Masinde MS, et al. A single-arm, proof-of-concept trial of lopimune (Lopinavir/Ritonavir) as a treatment for HPV-related pre-invasive cervical disease. PLoS One. 2016;11:e0147917.
Desravines N, Miele K, Carlson R, et al. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: a narrative review. Gynecol Oncol Rep. 2020;33:100608.
Kechagias KS, Kalliala I, Bowden SJ, et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ. 2022;378:e070135.
Lichter K, Krause D, Xu J, et al. Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis. Obstet Gynecol. 2020;135:1070–1083.
Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines (Basel). 2021;9:410.
Barra F, Della Corte L, Noberasco G, et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J Obstet Gynaecol Res. 2020;46:989–1006.
Harper DM, Nieminen P, Donders G, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase II trial with 2.5years of follow-up. Gynecol Oncol. 2019;153:521–529.
Ikeda Y, Adachi K, Tomio K, et al. A placebo-controlled, double-blind randomized (phase IIB) trial of oral administration with HPV16 E7-expressing lactobacillus, GLBL101c, for the treatment of cervical intraepithelial neoplasia grade 2 (CIN2). Vaccines (Basel). 2021;9:329.
Karimi-Zarchi M, Allahqoli L, Nehmati A, et al. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. BMC Public Health. 2020;20:274.
Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer. 2007;121:2794–2800.
Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004;23:172–181.
Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078–2088.
Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103:317–326.
Matijevic M, Hedley ML, Urban RG, et al. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. Cell Immunol. 2011;270:62–69.
Ventura C, Luis A, Soares CP, et al. The effectiveness of therapeutic vaccines for the treatment of cervical intraepithelial neoplasia 3: a systematic review and meta-analysis. Vaccines (Basel). 2022;10:1560.
Beiner ME, Hauspy J, Rosen B, et al. Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study. Gynecol Oncol. 2008;110:168–171.
Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016;17:e240–e253.
Noel P, Dube M, Plante M, et al. Early cervical carcinoma and fertility-sparing treatment options: MR imaging as a tool in patient selection and a follow-up modality. Radiographics. 2014;34:1099–1119.
Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331–5336.
Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–1904.
Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018;379:1905–1914.
Kadkhodayan S, Shiravani Z, Hasanzadeh M, et al. Lymphatic mapping and sentinel node biopsy in endometrial cancer--a feasibility study using cervical injection of radiotracer and blue dye. Nucl Med Rev Cent East Eur. 2014;17:55–58.
Wu Y, Li Z, Wu H, et al. Sentinel lymph node biopsy in cervical cancer: a meta-analysis. Mol Clin Oncol. 2013;1:1025–1030.
Ruscito I, Gasparri ML, Braicu EI, et al. Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol. 2016;23:3749–3756.
Frumovitz M, Plante M, Lee PS, et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2018;19:1394–1403.
Lecuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol. 2011;29:1686–1691.
Mathevet P, Lecuru F, Uzan C, et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: results of a multicentre randomised trial (SENTICOL-2. Eur J Cancer. 2021;148:307–315.
Ramirez PT, Pareja R, Rendon GJ, et al. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care. Gynecol Oncol. 2014;132:254–259.
Schmeler KM, Pareja R, Lopez Blanco A, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021;31:1317–1325.